EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vaccinex's enterprise value is $8.30 Mil.
Vaccinex's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-20.13 Mil. Therefore, Vaccinex's EV-to-EBITDA for today is -0.41.
The historical rank and industry rank for Vaccinex's EV-to-EBITDA or its related term are showing as below:
VCNX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.95 Med: -1.89 Max: -0.12
Current: -0.41
During the past 8 years, the highest EV-to-EBITDA of Vaccinex was -0.12. The lowest was -12.95. And the median was -1.89.
VCNX's EV-to-EBITDA is ranked worse than 100% of 462
companies
in the Biotechnology industry
Industry Median: 9.55
vs VCNX: -0.41
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-04), Vaccinex's stock price is $6.05.
Vaccinex's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-65.176. Therefore, Vaccinex's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Vaccinex EV-to-EBITDA Historical Data
The historical data trend for Vaccinex's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vaccinex's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaccinex's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vaccinex's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vaccinex's EV-to-EBITDA falls into.
Vaccinex EV-to-EBITDA Calculation
Vaccinex's EV-to-EBITDA for today is calculated as:
Vaccinex's current Enterprise Value is $8.30 Mil.
Vaccinex's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaccinex (NAS:VCNX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Vaccinex's share price for today is $6.05.
Vaccinex's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-65.176.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Vaccinex's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VCNX has been successfully added to your 